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Introduction 
 
 The chronic obstructive pulmonary disease (COPD) is defined as a: 
… common preventable and treatable disease, characterized by persistent airflow 
limitation that is usually progressive and associated with an enhanced chronic 
inflammatory response in the airways and the lung to noxious particles or gases. 
Exacerbations and comorbidities contribute to the overall severity in individual 
patients. 
 
 COPD involves chronic inflammation of the peripheral airways and lung 
parenchyma, which leads to progressive narrowing of the airways and shortness 
of breath. This inflammation is resistant to treatment with corticosteroids and 
there are currently no safe and effective alternative anti-inflammatory treatments 
(1).  
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Asthma and chronic obstructive pulmonary disease (COPD) are both very 
common and their incidence is increasing globally, placing an increasing burden 
on health services in industrialized and developing countries. Both diseases are 
characterized by airway obstruction, which is variable and reversible in asthma 
but is progressive and largely irreversible in COPD. In both diseases, there is 
chronic inflammation of the respiratory tract, which is mediated by the increased 
expression of multiple inflammatory proteins, including cytokines, chemokines, 
adhesion molecules, inflammatory enzymes and receptors. In both diseases there 
are acute episodes or exacerbations, when the intensity of this inflammation 
increases. The similarity between these airway diseases prompted the suggestion 
in the 1960s that asthma and COPD are different forms of a common disease 
(chronic obstructive lung disease) (Barnes 2008). 
 
The main types of COPD are the development of small-airway obstruction and 
emphysema, which can occur alone or together, but which both involve 
progressive airflow limitation and are usually caused by tobacco smoke. The 
differences in inflammation between asthma and COPD are linked to differences 
in the immunological mechanisms that underlie these two diseases. The 
appreciation that similar immune mechanisms are involved in both asthma and 
COPD has important implications for the development of new therapies for these 
troublesome diseases. 
Inflammation is present in the lungs, particularly the small airways, of all people 
who smoke. This normal protective response to the inhaled toxins is amplified in 
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COPD, leading to tissue destruction, impairment of the defence mechanisms that 
limit such destruction, and disruption of the repair mechanisms. In general, the 
inflammatory and structural changes in the airways increase with disease severity 
and persist even after smoking cessation. Besides inflammation, two other 
processes are involved in the pathogenesis of COPD—an imbalance between 
proteases and antiproteases and an imbalance between oxidants and antioxidants 
(oxidative stress) in the lungs.  
There is evidence for familial susceptibility in both COPD and lung cancer. This 
familial susceptibility appears to be linked and not just associated with the 
common consumption of cigarettes; implying that the underlying genetic 
predisposition to both diseases may be the same or reflect the link between the 
immune system, inflammation and cancer. Linkage studies have implicated 
regions in chromosome 6 as being linked to both diseases. Furthermore, GWAS 
studies in large COPD and lung cancer cohorts have found the same risk loci 
including CHRNA3 and CHRNA5 SNPs (15q) and regions at 4q31 (HHIP), 4q24 
(FAM13A) and 5q (HTR4). Nicotine addiction may explain the overlap in risk loci 
between lung cancer, smoking behavior and COPD. Epithelial to mesenchymal 
transition (EMT) and inflammation are pathogenic features of COPD and lung 
cancer and the rs7326277TT genotype in VEGFR1, which promotes 
inflammation, EMT and tumor growth, is a susceptible locus for both COPD and 
lung cancer. Several studies have demonstrated that polymorphisms in the anti-
inflammatory gene IL10 are associated with increased rates of lung and other 
cancer. (Durham AL 2015). 
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Increased production (or activity) of proteases and inactivation (or reduced 
production) of antiproteases results in imbalance. Cigarette smoke, and 
inflammation itself, produce oxidative stress, which primes several inflammatory 
cells to release a combination of proteases and inactivates several antiproteases by 
oxidation. The main proteases involved are those produced by neutrophils 
(including the serine proteases elastase, cathepsin G, and protease 3) and 
macrophages (cysteine proteases and cathepsins E, A, L, and S), and various 
matrix metalloproteases (MMP-8, MMP-9, and MMP-12). The main antiproteases 
involved in the pathogenesis of emphysema include !1 antitrypsin, secretory 
leucoprotease inhibitor, and tissue inhibitors of metalloproteases.  
The oxidative burden is increased in COPD. Sources of oxidants include cigarette 
smoke and reactive oxygen and nitrogen species released from inflammatory 
cells. This creates an imbalance in oxidants and antioxidants of oxidative stress. 
Many markers of oxidative stress are increased in stable COPD and are further 
increased in exacerbations. Oxidative stress can lead to inactivation of 
antiproteases or stimulation of mucous production. It can also amplify 
inflammation by enhancing transcription factor activation (such as nuclear factor 
"B) and hence gene expression of pro-inflammatory mediators. 
Mucous hypersecretion results in a chronic productive cough. This is 
characteristic of chronic bronchitis but not necessarily associated with airflow 
obstruction, and not all patients with COPD have symptomatic mucous 
hypersecretion. The hypersecretion is due to squamous metaplasia, increased 
numbers of goblet cells, and increased size of bronchial submucosal glands in 
response to chronic irritation by noxious particles and gases. Ciliary dysfunction 
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is due to squamous metaplasia of epithelial cells and results in an abnormal 
mucociliary escalator and difficulty in expectorating. 
 
The main site of airflow obstruction occurs in the small conducting airways that 
are < 2 mm in diameter. This is because of inflammation and narrowing (airway 
remodelling) and inflammatory exudates in the small airways. Other factors 
contributing to airflow obstruction include loss of the lung elastic recoil (due to 
destruction of alveolar walls) and destruction of alveolar support (from alveolar 
attachments).  
 The airway obstruction progressively traps air during expiration, resulting in 
hyperinflation at rest and dynamic hyperinflation during exercise. Hyperinflation 
reduces the inspiratory capacity and therefore the functional residual capacity 
during exercise. These features result in breathlessness and limited exercise 
capacity typical of COPD. The airflow obstruction in COPD is best measured by 
spirometry and is a prerequisite for its diagnosis. 
Gas exchange abnormalities occurs in advanced disease and are characterised by 
arterial hypoxaemia with or without hypercapnia. An abnormal distribution of 
ventilation: perfusion ratios due to the anatomical changes found in COPD is the 
main mechanism for abnormal gas exchange. The extent of impairment of 
diffusing capacity for carbon monoxide per litre of alveolar volume correlates 
well with the severity of emphysema (Mac Nee, 2006). 
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There are many differences between mild asthma and COPD in the type of 
inflammation that occurs in the lungs, with a different range of inflammatory cells 
and mediators being implicated. However, many of the cytokines and chemokines 
that are secreted in both asthma and COPD are regulated by the transcription 
factor nuclear factor-"B (NF-"B), which is activated in airway epithelial cells and 
macrophages in both diseases, and may have an important role in amplifying 
airway inflammation (Barnes 2008). 
Approximately 10% of patients with COPD have a reversibility of 
bronchoconstriction, showing greater than 12% improvement in lung function as 
assessed by forced expiratory volume in 1 second (FEV1), and therefore behave 
more like asthmatics. Furthermore, compared with most patients with COPD, 
these patients more frequently have eosinophils in their sputum, an increase in 
exhaled nitric oxide and respond better to corticosteroid treatment, all of which 
are characteristic features of asthma. It therefore seems likely that these patients 
have concomitant asthma and COPD (Barnes 2008). 
! )!
 
 
 
Epithelial cells are activated by cigarette smoke and other inhaled irritants, such 
as biomass fuel smoke, to produce inflammatory mediators, including tumor 
necrosis factor (TNF) alpha, interleukin (IL)-1 beta, IL-6, granulocyte-
macrophage colony–stimulating factor (GM-CSF), and CXCL8 (IL-8). Epithelial 
cells in small airways may also be an important source of transforming growth 
factor (TGF) beta which then induces local fibrosis. Vascular endothelial growth 
factor (VEGF) seems to be necessary to maintain alveolar cell integrity, and 
blockade of VEGF receptors (VEGFR2) in rats induces apoptosis of alveolar cells 
and an emphysemalike disorder. Airway epithelial cells are also important in 
defense of the airways, with mucus production from goblet cells, and secretion of 
antioxidants, antiproteases, and defensins. It is possible that cigarette smoke and 
! *!
other noxious agents may impair these responses of the airway epithelium, 
increasing susceptibility to infection. The airway epithelium in chronic bronchitis 
and COPD often shows squamous metaplasia, which may result from increased 
proliferation of basal airway epithelial cells but the nature of the growth factors 
involved in epithelial cell proliferation, cell cycle, and differentiation in COPD 
are not yet certain. Epithelial growth factor receptors (EGFR) show increased 
expression in airway epithelial cells of patients with COPD and can contribute to 
basal cell proliferation, resulting in squamous metaplasia and an increased risk of 
bronchial carcinoma (Barnes 2014). 
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Overlap 
Syndrome 
 
Asthma and COPD are two 
different diseases.  
Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) is a 
loosely-defined clinical entity referring to patients who exhibit characteristics of 
both asthma and chronic obstructive pulmonary disease (COPD).  
It has been well recognized that specific phenotypes exist in patients with COPD 
and asthma. It has been shown that patients with ACOS have increased 
reversibility of airflow, more exacerbations and more severe dyspnoea. 
Identifying patients with ACOS seems therefore relevant for the management of 
their disease. 
ACOS has been defined as two clinical phenotypes: asthma with partially 
reversible airflow obstruction, with or without emphysema or reduced carbon 
monoxide diffusion capacity (DLCO) to less than 80% predicted; and COPD with 
emphysema accompanied by reversible or partially reversible airflow obstruction 
with or without environmental allergies or reduced DLCO. A document from 
Global initiative for chronic obstructive lung disease (GOLD) and GINA 
described ACOS as persistent airflow limitation with several features usually 
associated with asthma and several features usually associated with COPD 
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[GINA-GOLD, 2015]. When a patient has similar numbers of features of  asthma 
and COPD, the diagnosis of ACOS could be considered (Slats A. 2015). 
The estimated prevalence of ACOS ranges from 12.1% to 55.2% among patients 
with COPD and 13.3%–61.0% among patients with asthma alone. In the general 
population of Italy, the prevalence of ACOS was 4.5% in the 65–84 age group. 
In COPD, eosinophilic inflammation has been shown during exacerbations both in 
induced sputum as well as in bronchial biopsies. In addition, blood eosinophilia 
was associated with increased mortality. Patients with COPD and eosinophilic 
inflammation during exacerbation usually have increased concentrations of 
peripheral eosinophils in stable disease as well. Some studies identified a set of 
airway epithelial genes that are altered in asthma, and in some current and former 
smokers with COPD. This ‘Th2 gene signature’, associated with asthma-like 
inflammation, is also expressed in COPD and is associated in those patients with 
eosinophilic inflammation, reversibility and favourable corticosteroid response as 
reflected by more improvement in hyperinflation. Improvement in hyperinflation 
in COPD is important since it is related to dyspnoea and exercise tolerance. 
 
Airway wall remodelling refers to alterations in the distinct aspects of the airway 
wall, that is, mucosal oedema, airway smooth muscle hypertrophy and 
hyperplasia, and thickening of basal membrane. This leads to airway wall 
thickening and altered airway mechanics. Airway remodelling occurs throughout 
the whole respiratory tract, including small airways. Both in asthma and COPD 
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there is evidence of airway wall thickening and remodelling, however the degree 
of changes in specific structures of the airway wall differ between asthma and 
COPD. In lots of studies, increased bronchial wall thickening has been 
demonstrated on high-resolution computed tomography scans in patients with 
overlap syndromes compared with COPD alone, but has not been compared in 
patients with asthma alone. In a small group of nonsmoking patients with asthma, 
a decrease in lung elastic recoil was demonstrated, with microscopic centrilobular 
emphysema in three autopsied patients. However, there are no data yet on whether 
the specific structures of airway remodelling differ in overlap syndrome compared 
with asthma and COPD alone. 
 
Data on medical treatment of patients with ACOS is rare because these patients 
has been systematically excluded from both COPD and asthma pharmacological 
trials. 
Understanding the reasons for differences in prevalence estimates of ACOS 
across the literature can help guide decision making on the most appropriate 
criteria for defining ACOS and aid investigators in designing future ACOS 
clinical studies aimed at effective treatment. 
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Cigarette smoke 
 
Cigarette smoking is the main risk factor in COPD and results in the imbalance of 
oxidant and antioxidant and increased airway inflammation in alveolar 
macrophages. 
Chronic airway inflammation is an archetypal feature of COPD, and increased 
oxidative stress has been suggested to be responsible for triggering inflammatory 
events observed within the lungs of smokers and COPD patients.  
The majority of smokers know that smoking is harmful to their health; and it is 
estimated that 50 % of smokers with COPD are amenable to smoking cessation 
support. However, results from smoking cessation intervention studies comparing 
smokers with and without COPD have yielded ambiguous results. Higher, equal 
and lower smoking cessation rates in smokers with COPD were found compared 
to smokers without COPD. Nevertheless, the prevalence of smoking in patients 
with COPD is still high and exceeds the rate of smoking in the general population. 
A large population-based study showed that the prevalence of smoking currently 
was 35 % among patients with COPD compared with 22 % among patients 
without COPD. This implies that when patients get a diagnosis of COPD many 
still continue smoking even though quitting is their best treatment option. Their 
chances of quitting might partly be reduced because of a higher level of tobacco 
addiction and susceptibility to develop depressive symptoms. Therefore, smokers 
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with COPD seem to be a special subgroup of smokers that have a more urgent 
need to quit smoking, but might find it more difficult to do so. 
Although the precise mechanisms behind the pathogenesis of COPD are yet to be 
fully dissected, the current hypothesis suggests that cigarette smoke causes airway 
inflammation by activating macrophages, neutrophils, and T lymphocytes, which 
release proteases and reactive oxygen species (ROS) leading to cellular injury. As 
a consequence, chronic inflammatory processes are triggered that lead to small 
airway obstruction. An estimated 10 to 15 % of all smokers develop clinically 
significant airflow obstruction (van Eerd EA 2015). 
An increased oxidant burden in smokers may be derived from the fact that 
cigarette smoke contains an estimated 1017 oxidants/free radicals and 4,700 
chemical compounds, including reactive aldehydes (carbonyls) and quinones, per 
puff. Many of these are relatively long-lived, such as tar-semiquinone, which can 
generate hydroxyl radicals ( OH) and H2O2 by the Fenton reaction. One 
consequence of this increased oxidative stress is activation of redox-sensitive 
transcription factors, such as NF-"B and activator protein-1 (AP-1), which are 
critical to transcription of proinflammatory genes (IL-8, IL-6, and TNF-!) (Yang 
SR. 2006). 
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In addition to exogenous reactive nitrogen and oxygen species (RNOS), 
mitochondrial respiration is a major source of RNOS generation and 
mitochondrial dysfunction is present in many cancers. RNOS damage cells 
through a number of mechanisms including DNA damage (especially 
mitochondrial DNA) lipid peroxidation, oxidation of amino acids and oxidation of 
inorganic enzyme co-factors (Durham AL 2015). 
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Oxidative Stress 
 
In the airways, oxidative stress, inflammation and protease-antiprotease imbalance  
represents the classic pathologic triad associated with chronic obstructive 
pulmonary disease (COPD) (Barnes 2014). 
Oxidative stress has been implicated in cell and tissue damage associated with 
many chronic inflammatory lung diseases such as asthma, COPD, idiopathic 
pulmonary fibrosis (IPF) and adult respiratory distress syndrome (ARDS). 
Increased ROS production has been directly connected to oxidation of protein, 
DNA, and lipids that may cause direct lung injury or induce a variety of cellular 
responses through the generation of secondary metabolic reactive species. 
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The pathogenesis of many forms of lung injury has implicated peroxidative 
breakdown of polyunsaturated fatty acids due to the effects on membrane 
function, inactivation of membranebound receptors and enzymes, and increased 
tissue permeability. There is increasing evidence that aldehydes, generated 
endogenously during the process of lipid peroxidation, are involved in many of 
the pathophysiological events associated with oxidative stress in cells and tissues. 
In addition to their cytotoxic properties, lipid peroxides are increasingly 
recognized as being important in signal transduction for a number of important 
events in the inflammatory response of the lungs. 
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ROS can alter the remodeling of extracellular matrix, apoptosis and mitochondrial 
respiration, cell proliferation, maintenance of surfactant and the antiprotease 
screen, effective alveolar repair responses and immune modulation in the lung. 
ROS secreted by phagocytes that have been recruited to sites of inflammation, are 
a major cause of the cell and tissue damage associated with many chronic 
inflammatory lung diseases such as asthma, COPD, IPF and ARDS. All these 
diseases involve the recruitment of immune and inflammatory cells to the lungs. 
These cells are activated and produce mediators of inflammation including ROS 
and cytokines, such as the pro-inflammatory cytokine tumor necrosis factor-! 
(TNF-!). 
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The response of a cell or organism to an increase in ROS normally involves the 
activation of numerous intracellular signaling pathways. These cytosolic pathways 
can regulate a host of transcriptional changes that allow the cell to respond 
appropriately to the perceived oxidative stress. In addition to the regulation 
achieved by classical cytosolic signaling pathways, such as the family of mitogen-
activated protein kinases, evidence suggests that certain transcription factors can 
directly or indirectly alter their activity, depending on cellular redox conditions 
(Rajendrasozhan S., 2008) . 
 
RNOS stimulates the production of inflammatory mediators either directly or 
indirectly. Cells directly detect RNOS via the ROS receptor/proto-oncogene 
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ROS1. ROS1 activates the phosphoinositide 3-kinase (PI3K)-mTOR signaling 
pathway and other proteins related to cell differentiation, proliferation, growth and 
survival including AKT1, MAPK1, MAPK3, IRS1 and PLCG2. Furthermore, 
ROS activates NF-"B thereby upregulating the expression of numerous immune 
and inflammatory genes. 
RNOS can alter protein structure and function by modifying amino acid residues, 
inducing protein dimerization, and interacting with Fe-S moieties or other metal 
complexes. In COPD these post-translational mechanisms include the nitration of 
histone deacetylase (HDAC) 2, leading to its inactivation and degradation 
resulting in the prolonged inflammatory phenotype seen in patients. Additionally, 
RNOS can modify various proteins, rendering them auto-antigenic (i.e., 
immunoinflammatory). Therefore oxidative stress can be a key cause of both 
proliferation (lung cancer) and inflammation (COPD) in the lungs (Durham AL 
2015). 
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Inflammatory mediators 
 
The degree of inflammation in patients with COPD increases as the disease 
progresses, with increased numbers of neutrophils, macrophages and lymphocytes 
(Hogg, J. C. et al. 2004) 
Chronic inhalation of irritants (for example, cigarette smoke, air pollutants…) 
initially activates pattern recognition receptors such as Toll-like receptors (TLRs) 
(Freeman, 2013), (Nadigel, 2011 ). This leads to the activation of an innate 
immune response, with increased numbers of neutrophils and macrophages as 
well as the activation of airway epithelial cells and mucus secretion. In later stages 
of the disease the adaptive immune response is activated, with increased numbers 
of T-and B lymphocytes, which may be organized into lymphoid follicles, and 
this involves an increase in the number and activation of dendritic cells (Vassallo, 
R. et al. 2010). The numbers of CD8+ cytotoxic T lymphocytes (CTLs) and 
CD4+ T helper 1 (TH1) cells are also increased, as well as CD4+ TH17 cells, 
which may further amplify neutrophilic inflammation (Majo, J. et al 2001; Di 
Stefano, A. et al 2009; Pridgeon, C. et al. 2011) . 
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IL-17 A 
 
Interleukin (IL)-17A is increasingly recognized as an important regulator of 
cellular immunity and is conventionally considered to arise predominantly from 
the ‘Th17’ (T helper 17 cells)-specific subset of Th cells (CD4 cells), which is 
phenotypically and functionally distinct from Th-1 and Th-2 cells and from T 
regulatory (Treg) cells (Park H., 2005). 
Most current evidence supports IL-17A as having an important role as a pro-
inflammatory cytokine uniquely positioned at the interface of innate and adaptive 
immunity (Ouyang, W  2008). IL-17A induces the release of secondary pro-
inflammatory chemokines and growth factors in most epithelial and mesenchymal 
cells leading, in turn, to the recruitment and accumulation of neutrophils [Laan, M 
1999]. Specifically, it is known that IL-17A stimulates the production of C-X-C 
chemokines (such as chemokine (C-X-C motif) ligand 8, CXCL8), granulocyte-
chemotactic protein-2 and growth-stimulatory cytokines such as granulocyte 
colony-stimulating factor (G-CSF) and granulocyte/macrophage colony-
stimulating factor (GM-CSF) (Prause, O 2003; Jones, C 2002). IL-17A, in 
particular, promotes neutrophil activity locally in inflamed tissues as judged by 
increased activity of myeloperoxidase, neutrophil elastase and matrix 
metalloproteinase (MMP)-9 after local administration of recombinant IL-17 
protein (Prause, O. 2004; Ivanov, S., 2007). 
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IL-17A has also been implicated in lung diseases including asthma. IL-17A 
promotes recruitment and survival of airway macrophages during allergen-
induced airway inflammation (Sergejeva, S ; 2005). IL-17A is increased in 
asthmatic BALF, sputum and blood (Molet, S., 2001; Chakir, J., 2003) and 
increased immunoreactivity for IL-17A in the asthmatic airway submucosa is 
associated with impaired lung function (Chakir, J., 2003). In IL-17A knockout 
(KO) mice, the allergen-induced airway hyper-reactivity to methacholine is 
significantly reduced (Nakae, S 2002). Systemic blockade of IL-17A also 
inhibited the allergen-induced accumulation of neutrophils in the airway 
(Hellings, P.W., 2003). Moreover, IL-17A levels correlate with neutrophil counts 
in the sputum of moderate to severe asthmatics (Bullens, D.M., 2006); in addition, 
IL-17 induces epithelial cells to release CXCL8, a chemokine that is important for 
the attraction of neutrophils (Kim V 2008). 
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Serum IL-17A levels are increased in patients with stable COPD compared to 
healthy smokers and nonsmokers, increase with COPD stage, and are inversely 
correlated with predicted forced expiratory volume in 1 second (FEV1) 
percentage. IL-17+ neutrophils are present in induced sputum from patients with 
stable COPD, but it remains unclear whether the sputum levels of IL-17A are 
increased in patients with stable COPD. There is a significant increase in the 
number of IL-17A+ immunoreactive cells in the bronchial submucosa of mild or 
moderate and severe COPD patients compared to control nonsmokers, and in the 
peripheral lungs of stable COPD patients compared to smokers with normal lung 
function and nonsmoking subjects ( Caramori G.; 2014). 
 
IL-8 
 
Neutrophil accumulation in the airways of patients with COPD is driven by 
increased release of cytokines exerting a chemotactic effect on these cells. Among 
them, an important role may be played by tumour necrosis factor ! (TNF-!) and 
interleukin 8 (IL-8 or CXCL 8). In addition, TNF-! and IL-8 levels are increased 
in the airways of patients with COPD, suggesting that these mediators may play 
an important role in the pathogenesis of the disease (Profita M., 2003). 
CXCL8 levels are markedly elevated in the sputum of patients with stable COPD, 
and are correlated with disease severity; blocking antibodies to CXCL8 and 
related chemokines inhibits certain types of neutrophilic inflammation in 
experimental animals. The neutralization of CXCL8 with a blocking antibody 
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significantly reduces the neutrophil chemotactic activity of sputum from patients 
with stable COPD; however, this reduction is only partial, indicating that other 
neutrophil chemotactic factors, such as leukotriene B4 and the activated 
complement factor C5a, are also involved. However, CXCL8 plays a major role in 
neutrophil chemotaxis caused by alveolar macrophage-derived conditioned media, 
and this is most effectively inhibited by dual antagonism of CXCR1 and CXCR2 
receptors ( Caramori G.; 2014) 
 
 
IKKa and IKKb are activated differently in asthmatic patients in comparison with 
patients with COPD and HSs and affected differently by the therapy (Gagliardo et 
al. (JACI 2011). These findings suggest that although IKKa and IKKb are both 
involved in the synthesis of IL-8, different proinflammatory circumstances might 
induce a different upstream regulation of the IKK/NF-kB pathway, associated 
with different pharmacologic response in patients with asthma and COPD. High 
levels of p-IKKa protein were present in patients with COPD and HSs, whereas 
they were present only in 4 asthmatic patients. The kinase activity assay 
demonstrated that IKKa activity was significantly higher in patients with COPD 
than in asthmatic patients and control subjects. 
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A number of recent studies have examined the effect of IL-17A on IL-8 secretion 
in airway epithelial cells and airway smooth muscle cells. Furthermore, it was 
observed that IL-17A induces epigenetic changes which in turn diminish the 
ability of glucocorticosteroids (GC) to inhibit IL-8 production from human 
bronchial epithelial cells (Albano G.D. 2013) 
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TSLP 
 
TSLP is a cytokine of the IL-7 family, is produced mainly by stromal cells, 
including mast cells, and is involved in the activation, expansion, and survival of 
T lymphocytes and dendritic cells. TSLP expression in the airway epithelium is 
inducible through a NF-"B-dependent pathway in airway epithelium. Its action is 
mediated by a heterodimeric receptor composed of IL-7R! and TSLP receptor 
(TSLPR). Some functions of TSLP and its receptor overlap that of IL-7 and its 
receptor, despite signaling predominantly through signal transducer and activator 
of transcription (STAT)-5 at variance with IL-7R!, and thus this represents an 
alternative pathway to the IL-7/IL-7R! axis. In human airway smooth-muscle 
cells, TSLPR signaling is mainly mediated by STAT3. In vitro TSLP and TSLP-R 
expression in human airway smooth-muscle cells is increased after chronic 
exposure to cigarette smoke extract, and TSLP is a mediator of cross talk between 
airway smooth-muscle and mast cells. TSLP and TSLP-R-blocking antibodies 
neutralize the increased contraction of airway smooth-muscle cells induced by 
cigarette smoke extract, suggesting a role for this pathway in bronchoconstriction.  
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TSLP has also been implicated in the induction of glucocorticoid resistance in Th 
cells during airway inflammation by controlling the phosphorylation of STAT5. 
In addition, TSLP may amplify alternatively activated airway macrophage 
polarization and chemokine production. An increased number of cells expressing 
TSLP mRNA has been reported in the bronchi of stable COPD patients and 
control smokers with normal lung function, and increased TSLP immunostaining 
has been shown in the smooth muscle of patients with stable COPD compared to 
nonsmoking subjects. Blocking antibodies have been developed, but there have 
been no studies on COPD so far ( Caramori 2014). 
 
 
The current view is that NF-"B signalling is essential for epithelial production of 
TSLP. Based in part on mouse studies in which TSLP has been overproduced or 
its gene knocked out, respectively, TSLP has emerged as a ‘master switch’ of 
Th2-type inflammation. Studies involving human cells have generated additional 
features compatible with involvement of TSLP in further aspects of COPD 
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immunopathogenesis. Thus, given an appropriate micro milieu, TSLP itself, or 
TSLP through priming of dendritic cells, may expand and proliferate cytotoxic T 
cells, which may be important in causing tissue destruction in COPD. TSLP may 
also induce generation of cytokines and cells potentially involved in development 
of bronchi-associated lymphatic tissue and autoimmunity, which are topical facets 
of severe COPD. These intriguing actions of TSLP, together with its increased 
occurrence in COPD lungs and its overproduction by virally stimulated bronchial 
epithelial cells from asthmatic and COPD donors, underpin the hypothesis that 
TSLP may contribute to exacerbations and development of severe asthma and 
COPD (Brandelius A., 2009).  
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NF-#B  
 
Nuclear Factor kappa B (NF-"B) is a transcription factor that regulates the 
expression of numerous genes involved in cell survival, apoptosis, and 
inflammation; it regulates the expression of multiple pro-inflammation genes and 
is thus a key player in maintaining immune system homeostasis.  
The basic scheme of NF-"B signaling consists of a series of positive and negative 
regulatory elements. 
Inducing stimuli trigger 
IKK activation leading to 
phosphorylation, 
ubiquitination, and 
degradation of I"B proteins. 
Released NF-"B dimers are 
further activated through 
various posttranslational 
modifications and 
translocate to the nucleus 
where they bind to specific 
DNA sequences and 
promote transcription of 
target genes. In its most 
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basic form, therefore, the pathway consists of receptor and receptor proximal 
signaling adaptor molecules; the IKK complex; I"B proteins; and NF-"B dimers. 
 
The NF-"B family of transcription factors consists of five members, p50, p52, p65 
(RelA), c-Rel, and RelB, encoded by NFKB1, NFKB2, RELA, REL, and RELB, 
respectively, which share an N-terminal Rel homology domain (RHD) responsible 
for DNA binding and homo- and heterodimerization. NF-"B dimers bind to "B 
sites within the promoters/enhancers of target genes and regulate transcription 
through the recruitment of coactivators and corepressors. The transcription 
activation domain (TAD) necessary for the positive regulation of gene expression 
is present only in p65, c-Rel, and RelB. As they lack TADs, p50 and p52 may 
repress transcription unless associated with a TAD-containing NF-"B family 
member or other proteins capable of coactivator recruitment. Constitutive binding 
of p50 or p52 homodimers to "B sites on NF-"B-responsive promoters may thus 
act to check NF-"B transactivation until displaced by transcriptionally competent 
NF-"B dimers (Hayden MS . 2008). 
The established model of I"B function posits that I"B! retains NF-"B dimers in 
the cytoplasm, thereby preventing their nuclear translocation and subsequent 
DNA binding; however, the situation is actually more complex. The crystal 
structure of I"B! bound to the p65/ p50 heterodimer reveals that the I"B! protein 
masks only the nuclear localization sequence (NLS) of p65, whereas the NLS of 
p50 remains exposed. The exposed NLS of p50 coupled with nuclear export 
sequences (NES) in I"B! and p65 leads to constant shuttling of I"B!/NF-"B 
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complexes between the nucleus and the cytoplasm, despite steadystate localization 
that appears almost exclusively cytosolic. 
IKK! and IKK# are both able to phosphorylate multiple members of the I"B 
family, although with differing specificities. For example, both IKK! and IKK# 
phosphorylate I"B! at Ser32 and Ser36 and I"B# at Ser19 and Ser23; however, 
IKK! is less efficient and consequently cannot complement IKK# knockout cells.  
Furthermore, both IKK! and IKK# prefer I"B! to I"B#, which is consistent with 
the difference in I"B! and # degradation kinetics—I"B# degradation is 
significantly slower than I"B! in most canonical pathways in which both are 
degraded . I"B! bound to NF-"B is thought to be a preferred substrate to free 
I"B! (Hayden MS . 2008). 
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NF-kB is activated in the airways of asthmatic patients and patients with COPD    
(Gagliardo 2011) , it is activated through phosphorylation and degradation of IkB 
by IkB kinase (IKK) complex that in turn lead to nuclear translocation of NFkB 
and subsequent transcription of NF-kB–dependent genes. Phosphorylation of IkB 
proteins is accomplished by IKKa and IKKb (Hacker 2006). 
Many studies have indicated that IKK! can be detected in both the cytoplasm and 
the nucleus whereas IKK# is detected predominantly in the cytoplasm, The 
observation of nuclear/cytoplasm shuttling of IKK! led to the discovery of the 
first nuclear role of IKK! in phosphorylating histone H3, which results in NF-"B-
mediated gene expression. Many studies provided an explanation of why IKK! is 
dispensable for I"B! degradation but remains essential for NF-"B-dependent 
transcription. Aside from nuclear regulation of NF-"B dependent gene 
transcription through chromatin modification in response to pro-inflammatory 
stimuli, nuclear IKK! also functions in apoptosis, cell cycle, and tumor 
progression in colorectal, breast, pancreatic, gastric, osteosarcoma, and prostate 
cancers  (Anest V, 2003; Yamamoto Y 2003). 
 
Epigenetic mechanisms 
 
 
Many lung diseases, including asthma, chronic obstructive pulmonary disease 
(COPD), cystic fibrosis, interstitial lung disease and acute respiratory distress 
syndrome, involve inflammation, with the coordinate expression of multiple 
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inflammatory genes in the lungs. These inflammatory genes code for the 
expression of cytokines, chemokines, enzymes that synthesize inflammatory 
mediators, inflammatory mediator receptors and adhesion molecules, resulting in 
a regulated influx and activation of inflammatory cells and stimulation of resident 
structural cells. Many of these inflammatory genes are regulated by 
proinflammatory transcription factors, including nuclear factor kappaB (NF-"B) 
and activator protein (AP)-1. These transcription factors orchestrate, amplify and 
perpetuate the inflammatory response and form the molecular basis of chronic 
inflammation. The term epigenetics; as currently used, refers to a change in gene 
expression which is heritable but that does not involve any change in DNA 
sequence.  
In response to injury, gene expression can be modified through epigenetic 
mechanisms, consisting in any modification of the genome or of gene expression 
not resulting from alteration in DNA nucleotide sequence (Hagood JS 2013). 
 
Post-translational modifications of histones play an important role in epigenetic 
regulation of gene expression, and thus have critical effects on environment-
mediated chronic lung diseases such as COPD and asthma . Since histones are 
post-translationally modified during disease progression, the identification of 
these patterns as well as the altered activity of the enzymes that ‘write’ and ‘erase’ 
these marks are important mechanisms for the understanding of human diseases. 
The most intensively studied modifications are histone acetylation and 
methylation which through the action of specific enzymes form marks that allow 
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‘readers’ of these marks to remodel chromatin producing the open chromatin 
structure associated with active gene transcription or a closed repressive 
chromatin state linked to a lack of active transcription. ( Mortaz E., 2011) 
 
 
Acetylation, deacetylation, methylation and other chromatin histone modification, 
can regulate genes transcription through promoters accessibility. Transcriptionally 
active, “open” euchromatin generally has hyperacetylated and hypomethylated 
histones, whereas more inactive heterochromatin tends to be hypoacetylated and 
hypermethylated. In addition to acetylation and methylation, which have been 
extensively studied (Campos El, 2009), histone can be phosphorylated, nitrated, 
ubiquitynilated, and SUMOylated. 
Histone acetyltransferases (HATs, including p300- CREB binding protein [CBP]-
associated factor, p300/CBP, and GCN5) and histone deacetylases (HDACs e.g., 
HDAC2 and SIRTUIN1 [SIRT1]) maintain the balance between histone 
acetylation and deacetylation. HATs affect the binding of DNA sequence-specific 
transcription factors and, subsequently, recruit coactivators or corepressors on 
gene-specific regions to form either coactivator or corepressor complexes (Wang 
H, 2001). It is well known that transcriptional coactivators possess intrinsic HAT 
(CBP/p300) and HDAC activities, suggesting that histone acetylation and 
deacetylation play a causal role in regulating gene transcription. It is generally 
accepted that increase in histone acetylation leads to increased gene transcription, 
while histone hypoacetylation is linked to decreased gene transcription . Histone 
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acetylation by HATs and deacetylation by HDACs are also linked to cell-cycle 
progression, proliferation, senescence, DNA repair, and recombination events, as 
well as proin- flammatory gene transcription, which can be affected by oxidative 
stress and redox signaling ( Sundar IK. 2013) 
Histone deacetylation by histone deacetylases (HDACs) removes acetyl moieties 
from lysine residues of histones, causing rewinding of DNA and hence silencing 
gene transcription. The HDAC family of enzymes has been reported to have 17 
isoforms, each differentially expressed and regulated in different cell types (De 
Ruijter AJ 2003). 
 
HDACs not only cause the inhibition of gene transcription but also directly affect 
the nuclear binding of transcription factors such as NF-"B. It was recently 
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reported that HDACs 1 and 2 play a key role in the regulation of cell proliferation 
and corticosteroid-mediated inhibition of proinflammatory mediator expression 
(Ito K 2000; Sambucetti LC 1999). 
Several reports have shown that HDACs 1–3 can also be associated with inactive 
RelA/p65 and play a role in the regulation of NF-"B-mediated gene transcription. 
Thus, changes in HDAC activity associated with RelA/p65 can enhance or repress 
NF-"B mediated gene expression. 
 Among several types of HDACs, HDAC2 is well characterized and reported to 
play a role in the regulation of inflammation and has been implicated in the 
dysregulation in smokers and patients with COPD. HDAC2 expression and 
activity is decreased in smokers, COPD subjects, and mild asthma patients and 
that there is a good correlation between cytokine production and HDAC activity 
in alveolar macrophages from smokers and non-smokers. Decreased 
levels/activities of HDAC2, i.e. disruption of the acetylation: deacetylation 
balance, may lead to sustained transcription of pro-inflammatory gene controlled 
by NF-"B, resulting in a chronic inflammatory response. Cigarette smoke extract-
mediated reduction in HDAC2 was associated with increased RelA/p65, and 
indicated RelA/p65 interacts with HDAC2 and RelA/p65 becomes available or 
retained in the nucleus for pro-inflammatory gene transcription when HDAC2 is 
decreased. In addition, it’s been demonstrated that in HDAC3, but not HDAC1, 
interact with RelA/p65, suggesting an important role of specific HDACs such as 
HDAC2 and HDAC3 in regulation of NF-"B signaling pathway particularly in 
response to cigarette smoke. The binding of NF-"B to HDAC2 presumably 
reflects the recruitment of HDAC2 to specific NF-"B target promoters. The 
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domains of HDAC2 and NF-"B that interact remain to be identified. It is unlikely 
that this interaction involves the DNA binding domain of NF-"B, because 
trichostatin A (TSA) treatment did not significantly interfere with DNA binding. 
HDAC2 has also been implicated in the anti-inflammatory effects of 
corticosteroids as ligand bound steroid receptors recruit HDAC2 to promoters of 
pro-inflammatory genes leading to deacetylation and transcriptional repression. 
However, a small proportion of severe asthmatics who smoke and severe COPD 
patients exhibit unresponsiveness towards high doses of oral corticosteroids. The 
current hypothesis indicates that cigarette smoke-induced oxidative stress alters 
the basal HDAC2 response via post-translational modifications and an induced 
net loss of HDAC2. The absence of HDAC2 or the presence of a defective 
HDAC2 protein may thus explain the abnormal inflammatory response and 
corticosteroid inefficiency in patients with COPD. Decreased HDAC2 protein 
expression and deacetylase activity observed in the macrophage of COPD patients 
is implicated in an impaired ability of dexamethasone to inhibit basal cytokine 
release in alveolar macrophages from COPD patients compared to casual 
smokers.  
Many studies have focused on establishing a link between decreased HDAC2 
expression and increased susceptibility to persistent inflammation, less is known 
on how HDAC2 expression is regulated in response to cigarette smoke-induced 
oxidative stress (Rajendrasozhan S., 2008) . 
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Increased acetylation of lysine (K) residues on histone H3 (K9, K14, K27) and H4 
(K5, K8, K12) results in neutralization of positive charge on histone tails and 
facilitates access to transcription factors (Chung S. 2011) 
 
 
Therapy 
 
Asthma is usually highly responsive to corticosteroid therapy and inhaled 
corticosteroids have become the mainstay of disease management. Corticosteroids 
suppress inflammation by inducing the recruitment of the nuclear enzyme histone 
deacetylase 2 (HDAC2) to multiple activated inflammatory genes, which leads to 
deacetylation of the hyperacetylated genes, thereby suppressing inflammation. 
By contrast, patients with COPD respond poorly to corticosteroid treatment, and 
even high doses of inhaled or oral corticosteroids fail to suppress inflammation. 
This appears to be related to decreased activity and expression of HDAC2 in the 
inflammatory cells and peripheral lungs of COPD patients. This is the result of 
increased oxidative and nitrative stress, which together generate peroxynitrite that 
nitrates tyrosine residues in HDAC2, impairing enzyme activity and decreasing 
expression. The poor response to corticosteroid treatment seen in patients with 
severe asthma, in asthmatics who smoke and during acute exacerbations may also 
reflect a reduction in HDAC2 protein levels and function, as oxidative and 
nitrative stress are also increased in these situations. So, patients with severe 
asthma have a relative corticosteroid resistance, and this is linked to impaired 
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HDAC2 function. Reversal of corticosteroid resistance may therefore be a useful 
therapeutic strategy in the future for patients with COPD and severe asthma. 
 
The objective of pharmacological treatment of chronic obstructive pulmonary 
disease (COPD) is to prevent and control symptoms, reduce the frequency and 
severity of exacerbations, and improve general health status and exercise 
tolerance. None of the classes of drugs currently used in the treatment of COPD 
are able to modify the progressive decline in lung function which is the hallmark 
of this disease. Smoking cessation is currently the only intervention which has 
been shown to reduce the progression of COPD (GICOPD 2001). To achieve this 
objective, behavioral therapy and pharmacological treatment such as the 
administration of bupropion (an antidepressant), and nicotine replacement therapy 
have proved useful. However, it is important to try to control symptoms of COPD 
with pharmacological treatment using the following general proposals (GICOPD 
2001):  
1) There should be a stepwise increase in treatment, according to the severity of 
the disease. The step-down approach used in the chronic treatment of asthma is 
not applicable to COPD.  
2) Treatment needs to be chronic and maintained at the same level for long 
periods of time, unless significant side effects or exacerbations occur.  
3) Since individual patient response to the pharmacological treatment is variable, 
it is important to monitor pharmacological treatment closely and, if necessary, 
adjust it frequently. Drugs currently recommended for the treatment of COPD are:  
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1) Bronchodilators (selective #2 -agonists, anticholinergic antimuscarinic agents 
and methylxanthines); 
 2) glucocorticoids; 
3) other types of medication (vaccines, antibiotics, !1- antitrypsin augmentation 
therapy, mucolytic agents, antioxidants, immunoregulators, antitussives and 
vasodilators). These drugs will be presented in the order in which they would 
normally be prescribed for the treatment of patients with COPD, based on the 
level of severity of the disease ( Montuschi P. 2006). 
 
 
Long-Acting !-Agonists 
 
During its development, salmeterol was found to have some antiinflammatory 
actions, specifically, inhibition of the release of proinflammatory cytokines from 
neutrophils in vitro. Subsequently, studies have indicated a potential for inhibition 
of an experimental inflammatory challenge in humans. Salmeterol reduces the 
frequency of acute exacerbations in COPD, but other than this and its well-
established action in augmenting the effects of inhaled corticosteroids, there is 
little evidence that salmeterol itself has clinically relevant anti-inflammatory 
effects. Similarly, the ultra-long-acting #-agonist, indacaterol, has shown trends 
toward reductions in acute exacerbations, although at dosages above those 
approved in the United States. 
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Tiotropium Bromide!
Tiotropium bromide, an anticholinergic agent, has also been shown to have anti-
inflammatory potential. Many cells in proinflammatory pathways have abundant 
cholinergic receptors that are accessible to anticholinergic agents, suggesting the 
potential for inhibiting the release of nonneuronal paracrine mediators of 
inflammation by anticholinergic agents. There is accumulating evidence that 
tiotropium, in particular, can have such actions both in vitro, and in vivo. A recent 
study of the inhibitory effect of tiotropium on the release of inflammatory markers 
from lipopolysaccharide-stimulated human airway epithelial cells and fibroblasts 
in vitro showed that IL-8 and NF-"B and other markers were substantially 
reduced. Similarly, an in vivo study of lipopolysaccharide-induced lung 
inflammation in guinea pigs showed that cellular proliferation and collagen 
deposition in the lungs were abrogated by tiotropium administration. Of particular 
interest is that all the previously mentioned effects of tiotropium were achieved by 
concentrations that were at or below the therapeutic plasma level following 
clinical inhalation in humans, and therefore were consistent with a relevant 
clinical effect. (Novel Antiinflammatory Therapies for COPD Nicholas J. Gross, 
MD, PhD, FCCP 2012) 
 
 
 
 
 
! %$!
Glucocorticoid resistance 
!
Glucocorticosteroids are the most effective anti-inflammatory treatments available 
for many inflammatory and immune disease, including asthma, rheumatoid 
arthritis, inflammatory bowel disease, and autoimmune disease. However, a few 
patients with these disease show a poor or absent response even to high doses of 
glucocorticoids. Other inflammatory disease, such as chronic obstructive 
pulmonary disease, interstitial pulmonary fibrosis, acute respiratory distresses 
syndrome, and cystic fibrosis, seem to be largely glucocorticoid resistant. Since 
chronic inflammatory disease are widespread and their prevalence is rising, 
glucocorticoid resistance or insensitivity represents an important barrier to 
effective treatment and accounts for substantial health care spending (Barnes, 
2009). 
In a small proportion of patients with glucocorticoid-resistant asthma, 
glucocorticoid receptors translocate normally to the nucleus after dexamethasone 
exposure, but do not acetylate Lys5; thus, transactivation of genes does not occur. 
These patients show a poor response to high-dose inhaled corticosteroids, but 
have fewer adverse events than patients with glucocorticoid resistance. This 
finding is because side-effects are mediated via GREs. Recruitment of HDAC2 to 
activated inflammatory genes is a major mechanism of gene repression by 
glucocorticoids. HDAC2 activity and expression is reduced in patients with some 
diseases that respond poorly to glucocorticoid treatment. For example, HDAC2 
expression and activity are very low in alveolar macrophages, airways, and 
peripheral lung in patients with COPD. Similarly, low HDAC2 expression has 
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been found in PBMCs and alveolar macrophages from patients with refractory 
asthma and in the airways of asthmatic patients who smoke. Overexpression of 
HDAC2 (by use of a plasmid vector) in bronchoalveolar macrophages from 
patients with glucocorticoid-resistant COPD restored glucocorticoid sensitivity to 
the level seen in controls. Whether HDAC2 expression is also reduced in 
glucocorticoid-resistant patients with other inflammatory diseases, such as 
rheumatoid arthritis and inflammatory bowel disease, has not yet been 
investigated; however, HDAC2 and SWI/SNF expression is reduced in 
glucocorticoid-resistant adenocarcinomas of patients with Cushing’s disease. The 
mechanisms for the inactivation of HDAC2 in COPD are now being studied; 
oxidative and nitrative stress might inhibit HDAC2. Since oxidative stress is 
frequently found in patients with severe and glucocorticoid-resistant inflammatory 
diseases, it might be an important mechanism of glucocorticoid resistance 
(Barnes, 2009). 
 
A novel strategy for the treatment of steroid-resistant/severe asthma and COPD is 
reversal of steroid resistance by interfering with the pathways that cause it. 
Understanding these pathways has highlighted several therapeutic targets, such as 
p38MAPK. Perhaps the most attractive target is HDAC2 because restoration of 
HDAC2 with a plasmid vector has been shown to restore steroid responsiveness 
in macrophages from patients with COPD that are normally resistant. 
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It is now well established that adding long-acting b2-agonists (LABAs) to ICSs 
improves asthma control to a greater degree than increasing the dose of ICS. 
Accumulating evidence suggests that LABAs might enhance the function of 
corticosteroids through increasing nuclear translocation of the GR, which 
increases the anti-inflammatory effects of corticosteroids. This suggests that 
LABAs might be able to overcome steroid resistance in asthmatic patients when 
this is due to reduced nuclear translocation of the GR, as discussed above. LABAs 
reverse the increased GR phosphorylation that is found in PBMCs of some 
patients with severe asthma. The GR phosphorylation at Ser226 induced in 
PBMCs by IL-2 plus IL-4 stimulation is reversed by the LABA formoterol though 
inhibition of JNK1 and p38MAPKg. The effects of formoterol might be mediated 
by activation of the phosphatase protein phosphatase A2, which reverses the 
phosphorylation of the GR and JNK1. However, this effect of formoterol is not 
inhibited by b2-receptor antagonists and is seen in cell-free systems, suggesting a 
receptorindependent effect. LABAs might also reverse steroid resistance induced 
by oxidative stress through a different mechanism involving inhibition of PI3Kd. 
Interestingly, both formoterol and salmeterol restore steroid responsiveness in 
PBMCs from patients with severe asthma, whereas only formoterol has this effect 
in cells from patients with COPD, suggesting that the full agonist effect of 
formoterol compared with the partial agonist effect of salmeterol might be 
necessary to reverse steroid resistance when there is a greater degree of oxidative 
stress. LABAs also enhance the steroid-induced increase in MKP-1 expression, 
thereby more effectively inhibiting p38MAPK and JNK, an effect that is mediated 
through protein kinase A (Barnes 2013). 
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There is an unmet need for safe and effective antiinflammatory treatments for 
COPD, but it has proved difficult to develop such drugs, despite the discovery of 
several logical targets. Blocking individual cytokines with blocking antibodies or 
blocking chemokine receptors has so far proved to be disappointing in clinical 
studies. Broadspectrum antiinflammatory treatments, such as PDE4 and 
proinflammatory kinase inhibitors, have often been poorly tolerated with side 
effects that limit the dose that can be used. For example, a PDE4 inhibitor, 
roflumilast, has significant antiinflammatory effects in COPD cells and animal 
models of COPD but the dose in patients with COPD is limited by side effects, so 
the therapeutic benefit is marginal. It may be necessary to develop potent inhaled 
drugs in order to reduce systemic exposure and side effects, but it has proved 
difficult to discover inhibitors with high local potency that are retained within the 
lungs. If systemic inflammation is derived from peripheral lung inflammation, 
inhaled antiinflammatory treatments should reduce systemic inflammation and 
may therefore reduce or treat comorbidities (Barnes 2014). 
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Aims of the study 
!
This study hypothesises that the IL-17A present in the induced 
sputum supernatant from COPD patients (or the human recombinant IL-
17A), induces  chromatin remodeling promoting IL-8 and TSLP release in 
bronchial epithelial cells.  
My idea is that the increased levels of IL-17A might alter the IL-8 
and TSLP production due to  
a markedly reduction of the nuclear HDAC2 expression and activity;  
a new nuclear activity of Ikkalpha, that throught acetylation of 
Histone H3 (Lisin 9),  can “open” the chromatin and increase the 
expression of proinflammatory genes;   
  Finally we hypothesises that Tiotropium, an anticholinergic drug 
usually used in the treatment of COPD, might be effective in the control of  
the above mentioned activity generated by Induced sputum of COPD 
patients and hrIL-17A involving the related production of IL-8 and TSLP. 
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Materials and Methods 
!
Patients 
!
We recruited three groups of subjects: healthy asymptomatic non-smoking 
subjects with normal lung function (HC) (n=14), symptomatic smokers with 
normal lung function (HS) (n=10), and COPD (n=16). The diagnosis of COPD 
and the assessment of its severity were defined and classified according to the 
criteria reported by the Global Initiative for Obstructive Lung Disease (GOLD) 
guidelines for COPD management (GOLD stage $I). COPD subjects with 
exacerbations within 1-month prior to the study were excluded. Patients with 
COPD had a smoking history of 10  pack years or more.  
All COPD patients were in stable conditions. All COPD patients who had routine 
chest X-rays and computed tomographic scans that showed obvious emphysema 
were excluded. All patients were characterized with respect to gender, age, 
smoking history, COPD symptoms, comorbidity, and current history of treatment. 
Exclusion criteria included the following: other systemic diseases, chronic 
bronchitis, chronic spontaneous, sputum production, other lung diseases, upper 
and lower respiratory tract infections, treatment with glucocorticoids or 
anticholinergics within 3 months before the study and treatment with long acting 
beta adrenergic agonists 15 days before the study.  
The local Ethics Committee approved the study, and participating subjects gave 
their informed consent. 
! %*!
Reversibility test to bronchodilator was performed to exclude an asthmatic 
component, and the increase in forced expiratory volume in the 1st second 
(FEV1) after salbutamol was lower than 12% and 200 ml compared with basal 
values, in all COPD subjects.  
 
Sputum induction and processing 
!
Sputum induction and processing were performed according to the method of the 
plugs. Briefly after the collection of the sputum, the selected plugs were diluted 
with 4 volumes of phosphate-buffered saline (PBS 1X; Gibco). The resulting 
suspension was vortexed for 30 s and then centrifuged at 1000 g for 20 min. The 
induced sputum supernatants (ISs) were then aspirated and frozen at – 80 C in 
separate aliquots for the subsequent biochemical analyses. The cells obtained 
from IS were then cytocentrifuged (Cytospin 2; Shandon, Runcorn, United 
Kingdom) and stained with May–Grunwald–Giemsa. For differential cell counts, 
2 independent investigators who counted at least 400 cells per slide read the slides 
blindly. 
 
Measurement of IL-17A, IL-8 and TSLP 
!
The levels of IL-17A were measured in ISs using a commercial available enzyme-
linked immunosorbent assay (ELISA) kit (R&D Systems. Inc, MN, USA). The 
lower limit of detection was 15 pg/ml. The levels of IL-8 were determined in ISs 
and in 16HBE supernatants, using commercial ELISA kits (R&D Systems. Inc, 
! &+!
MN, USA), according to the manufactures' specifications. The lower detection 
limit for IL-8 was <5 pg/ml. The levels of TSLP were determinated in ISs using a 
commercial available enzyme-linked immunosorbent assay (ELISA) kit (R&D 
Systems. Inc, MN, USA). The lower limit of detection was <5 pg/ml. 
 
 
 
 
 
Epithelial cell cultures 
!
The SV40 large T antigen-transformed 16HBE cell line (16HBE) was used for 
these studies. 16HBE is a cell line that retains the differentiated morphology and 
function of normal airway epithelial cells. The cells represent a clonal diploid 
(2n=6) cell line isolated from human lung. 16HBE cells were cultured as adherent 
monolayers in Eagle's minimum essential medium (MEM) supplemented with 
10% heat-inactivated (56° C, 30 min) fetal bovine serum (FBS), 1% MEM (non-
essential amino acids, Euroclone), 2 mM L-glutamine and gentamicin 250 µg/ml 
at 37° C in a humidified 5% CO2 atmosphere. Evidences showed that 16HBE are 
similar to primary normal human bronchial epithelial (NHBE) cells (Lonza, 
Brussels, Belgium), and bronchial epithelial cells (BECs) from bronchial 
brushings concerning the response to inflammatory stimuli and antiinflammatory 
drugs. 
! &"!
 
Bronchial epithelial cells stimulation 
!
16HBE cells (180,000 cells/well) were plated in standard six-well culture plates in 
MEM 10% FCS and grown to confluence (70–80%). After 1 h in 1 ml of MEM 
1% FCS, the 16HBE cells were stimulated with ISs (20%) from HC (n=6), HS 
(n=6), and COPD (n=6) subjects or with recombinant human (rh) IL-17A (20 
ng/ml) (n=6). Furthermore, ISs from COPD patients with the IL-17 concentrations 
closest to the median of the values were selected to stimulate 16HBE. 200 µl of 
ISs were incubated with an anti IL-17A Ab for 1 h at 37° C to neutralize the 
specific activity before the stimulation of 16HBE (n=6). To determine the effects 
of anticholinergic bronchodilator compounds on IL-17A activity, Tiotropium 
Spiriva® (100 nM) (Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, 
Germany) was added to 16HBE 30 minutes before the stimulation with ISs from 
COPD (n=6) or with rhIL-17A (20 ng/ml) (n=6). 16HBE were stimulated for 24 
hrs to test IL-8 and TSLP by ELISA and Real time PCR, for 4 hrs to test HDAC2 
and Ac-His H3 (k9,) and for 2 hrs to test IKK!.  
 
 
Total and cytoplasmic/nuclear protein extraction 
!
16HBE were washed with cold PBS and lysed in a buffer containing 10 mmol/L 
Tris-HCl (PH 7.4), 50 mmol/L NaCl, 5 mmol/L EDTA, 1% Nonidet P-40; 
! &#!
phosphatase inhibitors consisted of 20 mmol/L #-glycerophosphate, 0.3 mmol/L 
Na3VO4, and 1 mmol/L Benzamidine (ICN Biochemicals, Inc, Aurora, Ohio); and 
protease inhibitors consisted of complete protease inhibitor cocktail (Roche). 
Nuclear extracts were obtained by NE-PER Nuclear and Cytoplasmic Extraction 
Kit (Thermo Scientific) that provides for efficient cell lysis and extraction of 
separate cytoplasmic and nuclear protein fractions by centrifugation. 25–30 µg of 
lysate was then denatured under reducing conditions by boiling for 3 min in 50 
mM Tris-HCl (pH 6.8), 1% SDS, 2%"-mercaptoethanol, and 0.01% bromophenol 
blue. Total and cytoplasmic/nuclear protein extracts were analyzed by western 
blot.  
 
Western Blot Analysis 
!
Total and nuclear proteins were separated by SDS-PAGE and transferred by 
electrophoresis onto Immobilon-P membranes (Millipore, Bedford, MA). After 
transfer, the membranes were blocked overnight at room temperature in PBS 
containing 3% BSA and 0.5% Tween 20  and then incubated for 1 h at room 
temperature with the primary Abs. After washing, the blot was incubated for 45 
min with the appropriate horseradish peroxidase conjugated secondary Ab; bound 
Ab was detected using the ECL chemiluminescence detection system (Amersham-
Pharmacia, Biotech), according to the manufacturer’s instructions. Membranes 
were stripped and reprobed with housekeeping proteins "-actin or glyceraldehyde-
3-phosphate dehydrogenase Abs to normalize differences in protein loading. 
Autoradiographic films were scanned by densitometry and analyzed using the 
! &$!
NIH Image/Gel Plotting analysis program (National Institutes of Health, 
Bethesda, MD). Results were normalized and expressed as ratio of the tested 
protein band intensity with "-actin.  
 
 
Antibodies 
!
Rabbit anti-human IKK! and Anti-acetyl-Histone H3, were obtained from 
Millipore (Ca) and used  diluted 1:500. Mouse anti-human histone deacetylase 
(HDAC) 2,  mouse anti-human IL-8 (B-2) and rabbit anti-human IL-17 (H-132) 
Abs were obtained from Santa Cruz Biotechnology (Santa Cruz, Ca) and diluted 
1:100. Anti rabbit TSLP was obtained from ProSci incorporated (Ca). Finally, 
mouse monoclonal anti "-Actin Ab was obtained from Sigma (St. Louis, MO) and 
used diluted 1:20000. 
 
HDAC activity 
!
Cells were stimulated for 4 hrs with ISs from HC, HS, and COPD. Protein levels 
were determined using a BCA kit (Thermo Scientific, Rockford, IL, USA). 
HDAC activity was assessed in nuclear extracts by a fluorometric HDAC activity 
assay (BioVision, Mountainview, CA, USA) performed according to the 
manufacturer's instructions and expressed as fluorimetric units (F.U.) normalized 
to %g of protein. 
! &%!
 
Quantitative real-time reverse transcription-
polymerase chain reaction (RT-PCR) of IL-8 and 
TSLP 
!
Total RNA was extracted from 16HBE cells with TRIzol Reagent (Invitrogen) 
following the manufacturer’s instructions, and was reverse-transcribed into 
cDNA, using M-MLV-RT and oligo(dT) primer (Invitrogen). Quantitative real-
time PCR of IL-8 transcript was carried out on StepOne Plus Real-time PCR 
System (Applied Biosystems, Foster City, CA, USA) using specific FAM-labeled 
probe and primers (prevalidated TaqMan Gene expression assay for IL-8 
Hs00174103m1, TSLP Hs00263639m1, Assays on Demand, Applied 
Biosystems). IL-8and TSLP genes expression was normalized to glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) endogenous control gene. Relative 
quantitation of gene expression was carried out with the comparative CT method 
(2-&&Ct) and was plotted as fold-change compared to untreated cells chosen as the 
reference sample. 
 
Silencing 
!
To confirm that IKK-! is involved in HDAC2 translocation and Histon H3 
acetylation, we tested the effect of IKK-! silencing in human bronchial epithelial 
cells using specific siRNA transfection. 16HBE cells were plated in six well tissue 
culture plates and grown in medium containing 10% FBS without antibiotics until 
! &&!
60 to 80% confluence. IKK-! siRNA (10 µM; Santa Cruz Biotechnology, Inc.) 
was then added to 100 µl of siRNA transfection medium, and the reaction was 
performed according to the manufacturer’s instructions until complete cell 
transfection (7 hrs at 37°C). For optimal siRNA transfection efficiency, siRNA 
(10 µM; Santa Cruz Biotechnology, Inc.) containing a scrambled sequence, that 
did not lead to the specific degradation of any known cellular mRNA, was used to 
control non-specific effects. Finally, cells were stimulated with ISs from COPD 
(20%) patients for 24 hrs and total and nuclear protein were extracted. The 
silencing efficacy of IKK-! RNA interference was assessed by Western blot 
analysis. 
 
 
 
Co-immunoprecipitation 
!
16HBE cells were washed with cold PBS 1X before lysing in mild protein lysis 
buffer (50 mM Tris ' HCl, 150 mM NaCl, 10 mM EDTA, 0.1% Nonidet P-40) 
with protease and phosphatase inhibitors. The cell lysate was precleaned with 
protein A agarose beads (Protein A/GPlus-Agarose, Santa Cruz Biotechnology, 
Santa Cruz, CA) and subsequently incubated overnight with a rabbit Anti-acetyl-
Histone H3 antibody (pull-down). Protein A agarose beads were added and 
incubated for 1 h at 4 °C. The immunoprecipitates (IP) were washed and boiled in 
2 ( SDS sample buffer for 5 min, centrifuged and cell lysates separated on 10% 
! &'!
SDS/PAGE gels for Western blot using a rabbit anti-human IKK! Ab. Non 
immunized IgG was applied as the pull-down control to confirm the binding 
specificity. Total protein without IP was run at the same time as control.  
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Results 
!
!
!
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Demographic characteristic of patients and 
differential cell counts of IS.  
!
The patient characteristics are summarized in Table 1. The results of the 
differential cell counts of induced sputum samples showed a significant increase 
in the number of cells in HS and COPD subjects. In HS, this increase reflected an 
increase in the number of both macrophages and neutrophils, whereas in COPD 
subjects neutrophils showed a large increase with the number of macrophages 
being significantly lower than in HS and in HC. Eosinophils resulted significantly 
! &*!
higher in COPD subjects than in HC, whereas lymphocytes did not show 
significant differences among the three study groups (Table 2). 
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Levels of IL-17A, TSLP and IL-8 in ISs. 
IL-8 and TSLP concentrations showed significantly higher levels in ISs from HS 
subjects and from COPD patients compared to ISs from HC subjects; and in ISs 
from COPD patients compared to ISs from HS subjects (Figure 1 A and C). 
Furthermore, IL-17A concentrations were significantly higher in ISs from COPD 
patients and from HS subjects than in HC (Figure 1 B). 
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Effect of ISs on IL-8 and TSLP release in 16HBE 
cells 
!
Protein extract from 16HBE showed a significant increase of IL-8 and TSLP 
proteins expression when the cells were stimulated with ISs from COPD patients 
and from HS subjects compared to HC  (Figure 2, A and B). 16HBE stimulated 
with Tiotropium (100 nM) or with ISs from COPD patients pretreated with an anti 
IL-17A Ab significantly reduced the expression of IL-8 and TSLP compared to 
16HBE stimulated with ISs from COPD patients (Figure 2, C and D).  
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IL-8/ TSLP mRNA levels in bronchial epithelial 
cells stimulated with IL-17A and ISs of COPD 
patients. Effect of Tiotropium. 
 
RT-PCR analysis of IL-8 and TSLP mRNA showed that 16HBE stimulated with 
hrIL-17A (fig.3, A and B )  or with ISs from COPD showed higher levels of 
mRNA expression (as indicated by the lower number of amplification cycles 
required) compared to untreated cells or to 16HBE pretreated with Tiotropium 
(100 nM) or to 16HBE stimulated with ISs from COPD treated with anti IL-17A 
(Figure 3, C and D)  
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ISs of COPD induce IL-8 / TSLP proteis 
productions. Effect of Tiotropium.  
!
The stimulation of 16HBE with ISs of COPD significantly increased the 
production of IL-8 and TSLP in cell protein extract compared to untreated cells. 
The preincubation of the 16HBE with Tiotropium or anti-IL-17 A, significantly 
reduced the effect of ISs on the IL-8 and TSLP production (Figure  4) 
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Chromatin remodelling after ISs treatment 
!
ISs from COPD patients and HS subjects, significantly decreased the levels of 
nuclear HDAC2 protein obtained by western blot analysis (Figure 5, A) as well as 
the levels of nuclear HDAC activity obtained by fluorometric assay (Figure 5, B) 
in 16HBE compared to untreated cells. Furthermore, ISs from COPD patients and 
HS subjects significantly decreased the levels of nuclear HDAC2 protein in 
16HBE compared to the cells stimulated with ISs from HC (Figure 5, A). 
Accordingly, the levels of nuclear HDAC activity (Figure 5, B) significantly 
decreased in 16HBE stimulated with ISs from COPD patients and HS subjects 
compared to the cells stimulated with ISs from HC. Additionally, we showed that 
the treatment of the 16HBE with Tiotropium (100 nM) significantly reduced 
HDAC2 translocation from the cytoplasm to the nucleus as well as HDAC 
activity in the cells stimulated with ISs from COPD patients compared to the cells 
treated with COPD ISs alone. Furthermore, we showed that the stimulation of the 
cells with ISs from COPD patients, pretreated with an anti-IL-17A antibody, 
significantly increased HDAC2 translocation from the cytoplasm to the nucleus 
and HDAC activity in 16HBE compared to the cells treated with ISs from COPD 
alone (Figure 5, E and F). Finally, we detected that the nuclear levels of HDAC2 
expression and activity was significantly reduced in 16HBE stimulated with rhIL-
17A compared to untreated cells. The preincubation of the cells with Tiotropium 
significantly reduced the effect of rhIL-17A on the nuclear levels of HDAC2 
expression and activity (Figure 5, C and D). 
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figure 6 
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COPD patients (Figure 6, C). These findings support an opposite tendency 
between Ac-His H3 (k9) and HDAC2 at the nuclear levels. 
The nuclear IKK! protein level is higher in the cells stimulated with ISs from 
COPD patients compared with untreated 16HBE. Furthermore, the pretreatment 
of the cells with Tiotropium (100 nM) significantly reduced the translocation of 
nuclear IKK! protein level compared to the cells stimulated with ISs from COPD. 
Furthermore, the stimulation of 16HBE with ISs from COPD patients treated with 
an anti-IL-17A antibody, significantly reduced the levels of nuclear IKK! 
compared to the 16HBE treated with ISs from COPD patients (Figure 6, B). 
Finally, we showed that the nuclear levels of Ac-His H3 (k9) and IKK! were 
significantly increased in 16HBE stimulated with rhIL-17A compared to untreated 
cells. The preincubation of the cells with Tiotropium significantly reduced the 
effect of rhIL-17A on the nuclear levels of Ac- His H3 and IKK! (Figure 6, A). 
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Figure 7 
!
Effect of IKK alpha silencing on HDAC 2, Histone 
H3 and IL-8/TSLP expression. 
!
Temporary transfection of 16HBE cells with IKK! siRNA caused a statistical 
significant decrease in the synthesis of IKK! protein in 16HBE compared with 
unsilenced cells. The silencing efficacy of the RNA interference for IKK! was 
40±3.6% (Figure 7, A). The IKK! silencing showed a statistically significant 
increased HDAC2 protein expression in 16HBE compared to unsilenced cells. 
Furthermore, Histone H3 ac (k9) protein expression significantly decreased in 
IKK! silenced cells compared to untreated. Finally the treatment of 16HBE with 
! ')!
scrambled siRNA sequence do not affect IKK alpha, HDAC 2 and Histone H3 
compared to unsilenced 16HBE (Figure 7, B). The silencing of IKK! protein 
significantly increased HDAC2 protein  and significantly reduced Ac-His H3 (k9) 
protein expression in 16HBE stimulated with  20% ISs of COPD patients 
compared to unsilenced stimulated cells (Figure 7, C). !
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IL-8 protein expression in Ikkalpha silenced cells 
!
IL-8 protein expression showed lower levels in cell lysates from untreated 16HBE 
silenced for IKK! protein compared to unsilenced cells (p<0.001) (Figure 8, A) as 
well as in 16HBE silenced stimulated for 24 hours with COPD  ISs and compared 
to unsilenced cells stimulated with ISs (p<0.038) (Figure 8, B). 
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TSLP protein expression in 16HBE silenced for 
IKK$ 
!
TSLP protein expression showed lower levels in cell lysate from untreated 
16HBE silencd for IKK! protein compared to unsilenced cells, as well as 16HBE 
silenced stimulated for 24 hours with IL-17A 20 ng/ml or with COPD ISs and 
compared to unsilenced cells stimulated with IL-17A or Iss (Figure 9) 
 
 
Figure 10 
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We next evaluated the interaction between Ac-His H3 (k9) and IKK! proteins 
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17A significantly induced an increase of cross coupling between IKK! and Ac-
His H3 (k9) compared to untreated 16HBE. The preincubation of the 16HBE with 
Tiotropium or the depletion of IL-17A in ISs significantly reduced the effect of 
stimulation with ISs from COPD patients (Figure 10). These findings might 
suggest a role of IKK! in the mechanism of His H3 acetylation in K9 involving 
pro-inflammatory IL-8/TSLP genes expression in 16HBE. 
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Discussion 
!
!
In this study we described, using an in vitro model obtained by induced sputum 
samples and bronchial epithelial cell line 16HBE, the immunological link between 
the levels of IL-17A, IL-8 and TSLP measured in the induced sputum 
supernatants from COPD patients. Particularly, we showed that IL-17A generated 
molecular mechanisms of chromatin remodeling, through HDAC2 translocation 
and Histone H3 acetylation by IKK! activity. This molecular activity of IL-17A 
promoted IL-8 and TSLP production in bronchial epithelial cells. Finally, we 
provided evidences that Tiotropium (non-selective anticholinergic drug blocking 
muscarinic receptors) was able to counteract the proinflammatory activity of IL-
17A.  
Acting as a physical barrier, the lung epithelium regulates lung fluid balance, 
modulates metabolism and clearance of inhaled agents, and secretes numerous 
mediators, several of which recruit and activate inflammatory cells in response to 
injury.  
Dysregulation of airway epithelial cell function may contribute to the 
pathogenesis of major lung diseases such as COPD. Th17 immunity and the 
related cytokines such as IL-17A are involved in both innate and adaptive aspects 
of airway immunity, representing a crucial crosstalk between the immune system 
and structural cells. It has been reported that IL-17A levels are increased in 
submucosal biopsy specimens from the large airways of patients with COPD 
compared to control subjects. These data support the involvement of IL-17A in 
the airway inflammation of COPD patients promoting, alone or in combination 
! ($!
with other cytokines, the production of IL-6, IL-8, and ICAM-1 in primary 
epithelial cells. 
Environmental factors such as Toll- like receptors ligands, viruses, microbes, 
allergen sources, cigarette smoke and proinflammatory citokines trigger TSLP 
production. An increased number of cells expressing TSLP mRNA has been 
reported in the bronchi of stable COPD patients and control smokers with normal 
lung function, and increased TSLP immunostaining has been shown in the smooth 
muscle of patients. 
 We detected higher levels of IL-17, IL-8 and TSLP in the samples of ISs from 
COPD and healthy smokers than in control subjects. Accordingly with previous 
study, these findings suggest a link between IL-17A and IL-8 in the airways of 
smoking COPD patients supporting the crosstalk between the cells of the immune 
system producing IL-17A and activated epithelial cells producing IL-8 observed 
during innate and adaptative immunity of the airways.  
In vitro studies have shown that differentiated cell culture is an invaluable model 
in understanding the physiological properties of the human airway epithelium. 
Much of our knowledge from the interactions between environmental and 
inflammatory stimuli, and the airway epithelium has been derived extensively 
from in vitro cell culture models using transformed cells 16HBE. Accordingly, we 
studied the effect of ISs from COPD, HS and HC on IL-8 and TSLP production in 
16HBE. The analysis of protein and mRNA clearly demonstrated that ISs from 
COPD and HS are able to increase the IL-8 and TSLP production rather than HC 
in 16HBE. Although the levels of IL-8 are not reflective of the levels of IL-17A 
since we did not identified a positive correlation between the two cytokines in ISs 
! (%!
from COPD, we observed that the depletion of IL-17A in ISs from COPD patients 
reduced the levels of IL-8 and TSLP mRNA transcripts and protein productions in 
16HBE. These findings might support the role of IL-17A in the epithelial cells 
activation during the inflammatory process of COPD. However, we underline that 
the anti-IL-17A treatment had different levels of inhibition on IL-8/TSLP mRNA 
and IL-8/TSLP proteins probably for a different time of mRNA stability and 
proteins half-live.  
The inflammatory pattern that occurs in COPD, with increased numbers of 
neutrophils and increased amounts of IL-8 and tumor-necrosis factor, increased 
oxidative stress and a poor response to corticosteroids. Anticholinergic drugs 
including Tiotropium, currently used for the treatment of COPD, block the 
activation of airway secretory cells and smooth muscle and so, theoretically, may 
reduce vagal tone and mucus secretion in COPD facilitating cough-induced 
mucus clearance. However although Tiotropium reduces exacerbation frequency 
in COPD, this effect does not appear to be due to a reduction in airway or 
systemic inflammation. Therefore, many studies suggest novel pharmacological 
strategies using Tiotropium as anti-inflammatory and anti-remodeling drugs in 
COPD. In vitro, it was observed that Tiotropium is able to control IL-8 and TSLP 
release from bronchial epithelial cells. Furthermore, IL-17A induces epigenetic 
changes, which in turn diminishes the ability of glucocorticosteroids (GC) to 
inhibit IL-8 production from human bronchial epithelial cells. In this study, we 
showed that the pretreatment of 16HBE with Tiotropium might be able to control 
the production of IL-8 and TSLP in term of protein and mRNA generated by IL-
17A and by proinflammatory mediators present in ISs from COPD. In this 
! (&!
scenario, the growing understanding of the epithelium and its interactions with 
inflammatory cells obtained by our findings might open new pharmacological 
perspectives to treat the epithelial dysregulation associated with Th17 immunity 
during inflammatory lung conditions. 
 
In light of these observations, we speculate that blockade of IL-17A downstream 
involving the pretreatment of epithelial cells with Tiotropium, might represent a 
new strategy for therapeutic intervention in GC-insensitive airway inflammation 
of COPD patients. Furthermore we suggest that, since the inflammatory 
components present in the airways of COPD patients are able to promote a 
deregulation of muscarinic AChReceptors expression and muscarinic 
AChReceptors activation in bronchial epithelial cells, this action might be 
exercised by IL-17A present in the ISs from COPD. This observation might 
justify the antinflammatory role of Tiotropium in our in vitro model of 16HBE. 
However, further studies might be necessary to clarify this concept. 
The HDAC family of enzymes has been reported to have 17 isoforms, each 
differentially expressed and regulated in different cell types playing a role in the 
regulation of cell proliferation and inflammatory responses. IL-17A induces GC 
insensitivity, probably mediated by PI3K activation and subsequent reduction of 
HDAC2 activity, in airway epithelium. Our findings showed that ISs from COPD 
patients, rather than ISs from HC subjects or untreated cells, generated a reduction 
of HDAC2 translocation from cytoplasm to the nucleus in 16HBE cells. The 
depletion of IL-17A with anti IL-17A antibody in ISs from COPD patients or the 
pretreatment of 16HBE with Tiotropium restored the nuclear levels of HDAC2 in 
! ('!
the cells stimulated with ISs from COPD patients. Our findings might suggest that 
anticholinergic drugs exert an anti-inflammatory role on IL-17 activity controlling 
chromatin remodeling that involved the release of inflammatory cytokines such as 
IL-8 and TSLP. However, further study might be necessary to clarify whether the 
specific inhibition of HDAC2 activity reduces the levels of IL-8 and TSLP 
production in 16HBE stimulated with ISs and IL-17A. 
The acetylation status of histones is controlled by the opposing actions of two 
classes of enzymes: histone acetyltransferases (HATs), which transfer acetyl 
groups to lysine residues within the N-terminal tails of core histones, and histone 
deacetylases (HDACs), which remove the acetyl groups. The acetylation status of 
histones influences chromatin conformation and affects the accessibility of 
transcription factors and effector proteins to the DNA, thereby modifying gene 
expression. It is known that inflammation can induce a chromatin remodeling 
through different molecules; the acetylation of Histone H3 in lysin 9 is a 
modification that facilitates the access to the promoter of the transcription 
complex. The kinase IKK! has a cytoplasmatic and nuclear function. The 
shuttling into the nucleus is crucial for his function as chromatin kinase and 
acetylase inducing specific modification of Histones. This implies a different 
expression of genes in response to an inflammatory stimulus. Cigarette 
smoke/TNF!-induced acetylation of histone H3 and inflammation through 
differential activation of IKK! in human lung epithelial cells. In this study, we 
showed that 16HBE cells treated with ISs from COPD patients increased the 
nuclear levels of IKK-!  and Ac-H3 k9 compared to untreated cells. The 
pretreatment of 16HBE with Tiotropium or the depletion of IL-17A in ISs from 
! ((!
COPD patients restored the basal levels of IKK! and Ac-H3 k9 as well as the 
basal levels of IL-8 and TSLP production. These findings suggest that IL-17A and 
inflammation present in the airways of COPD patients might generate IL-8 and 
TSLP production trough chromatin remodeling mechanisms involving the 
IKK! mediated acetylation of histone H3 in the gene promoter of IL-8 and TSLP 
in bronchial epithelial cells. The anticholinergic Tiotropium might act as 
antinflammatory drug controlling these mechanisms. Furthermore we found that 
IKK! silencing promoted the increase of nuclear levels of HADAC2, a reduction 
of the Ac H3 (k9) and of IL-8 and TSLP synthesis in 16HBE treated with ISs 
from COPD patients compared to unsilenced cells. Finally, the cellular extract 
from 16HBE (co-immunoprecipitated with anti Ac-His H3 (k9) and revealed with 
anti-IKK!) showed higher levels of IKK! in 16HBE stimulated with ISs from 
COPD patients or IL-17 A than in the cells pretreated with Tiotropium or than in 
the cells stimulated with ISs depleted of IL-17A. All together, these findings 
suggest that IL-17A present in the airways of COPD patients might be able to 
generate IKK! activation that in turn is able to control acetylation of Ac-His H3 
(k9). Finally, our results suggest that the anticholinergic drug might exert its 
antinflammatory role controlling molecular mechanism involving 
IKK! activation generated by IL-17A and the related synthesis of IL-8 and TSLP 
in bronchial epithelial cells. 
 
! ()!
Conclusions 
 
In conclusion, we demonstrate the anti-inflammatory effects of an anticholinergic 
drugs on IL-17A mediated chromatin remodeling mechanisms promoting IL-8 
and TSLP release in bronchial epithelial cells. These findings might suggest the 
use of Tiotropium as an useful alternative therapy to control IL-17A induced 
glucocorticoid insensitivity in human bronchial epithelial cells during COPD. 
The study of Induced sputum could be an important instrument in the 
personalized therapy of the chronic disease. With these  different approach, the 
therapeutic strategy could be more targeted and specific for any patients, reducing 
costs and optimizing drug administrations. 
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